Background
The potential effects of SARS-CoV-2 and
Plasmodium falciparum
co-infection on host susceptibility and pathogenesis remain unknown. We aimed to establish the prevalence of malaria and describe the clinical characteristics of SARS-CoV-2 and
P falciparum
co-infection in a high-burden malaria setting.
Methods
This was an exploratory prospective, cohort study of patients with COVID-19 who were admitted to hospital in Uganda. Patients of all ages with a PCR-confirmed diagnosis of SARS-CoV-2 infection who had provided informed consent or assent were consecutively enrolled from treatment centres in eight hospitals across the country and followed up until discharge or death. Clinical assessments and blood sampling were done at admission for all patients. Malaria diagnosis in all patients was done by rapid diagnostic tests, microscopy, and molecular methods. Previous
P falciparum
exposure was determined with serological responses to a panel of
P falciparum
antigens assessed using a multiplex bead assay. Additional evaluations included complete blood count, markers of inflammation, and serum biochemistries. The main outcome was overall prevalence of malaria infection and malaria prevalence by age (including age categories of 0–20 years, 21–40 years, 41–60 years, and >60 years). The frequency of symptoms was compared between patients with COVID-19 with
P falciparum
infection versus those without
P falciparum
infection. The frequency of comorbidities and COVID-19 clinical severity and outcomes was compared between patients with low previous exposure to
P falciparum
versus those with high previous exposure to
P falciparum
. The effect of previous exposure to
P falciparum
on COVID-19 clinical severity and outcomes was also assessed among patients with and those without comorbidities.
Findings
Of 600 people with PCR-confirmed SARS-CoV-2 infection enrolled from April 15, to Oct 30, 2020, 597 (>99%) had complete information and were included in our analyses. The majority (502 [84%] of 597) were male individuals with a median age of 36 years (IQR 28–47). Overall prevalence of
P falciparum
infection was 12% (95% CI 9·4–14·6; 70 of 597 participants), with highest prevalence in the age groups of 0–20 years (22%, 8·7–44·8; five of 23 patients) and older than 60 years (20%, 10·2–34·1; nine of 46 patients). Confusion (four [6%] of 70 patients
vs
eight [2%] of 527 patients; p=0·040) and vomiting (four [6%] of 70 patients
vs
five [1%] of 527 patients; p=0·014] were more frequent among patients with
P falciparum
infection than those without. Patients with low versus those with high previous
P fal...